News | June 13, 2011

Molecular Imaging Detects Signs of Genetic Heart Disease Before Symptoms Arise


June 13, 2011Research being presented at Society of Nuclear Medicine’s (SNM) 58th annual meeting shows that molecular imaging is helping to identify and treat a silent killer. A study focusing on hypertrophic cardiomyopathy (HCM) — a cardiovascular disorder that causes a thickening of the heart muscle — is proving that the effects of a genetic mutation may be an important key to understanding the disease. In related research, a treatment called alcohol septal ablation is being revealed as an effective treatment for severe cases of HCM.


“These studies show that molecular imaging has great potential for clinical use in the field of cardiology,” said Stefan Timmer, M.D., of Free University Medical Centre, Amsterdam, The Netherlands. “HCM is usually asymptomatic, and one of the first symptoms is acute death due to arrhythmia, which demonstrates how essential it is to detect this disease. We used molecular imaging to gauge the heart’s efficiency in subjects with a pathogenic mutation linked to HCM. Unexpectedly, we found that carriers of the mutation already have a less efficient heart despite the absence of any symptoms. In addition, the research provides a suggestion why a frequently used therapy, alcohol septal ablation, is an effective treatment for symptomatic patients who remain symptomatic despite optimal medical treatment.”


The abnormal thickening of the muscle, or myocardium, involved in HCM makes it harder for the heart to contract and relax, forcing the heart to work harder to pump blood. HCM is often asymptomatic and can cause sudden cardiac death at any age. The pathophysiology of HCM is not well understood. However, preclinical research points toward genetic mutations, such as MYBPC3, which are exclusive proteins in the heart’s contractile tissue.


In one study, researchers imaged 16 subjects with the MYBPC3 mutation using positron emission tomography (PET) in order to image the heart’s oxygen usage. This was coupled with cardiovascular magnetic resonance imaging (MRI) to gauge the heart’s ability to use energy efficiently. To their surprise, patients carrying the MYBPC3 mutation were shown to have less efficient hearts even prior to the thickening and subsequent symptoms associated with HCM, which makes it a prime causal candidate for the development of the disease.


For HCM patients who remain symptomatic despite medication, alcohol septal ablation is a popular treatment. It is essentially a miniature, controlled heart attack triggered by an absolute alcohol solution administered to the septal artery that provides blood flow to the thickened heart muscle. Interventional cardiologists perform the non-invasive therapy using wires and balloons guided to the artery. There are few complications associated with the procedure, and it is the preferred treatment over open-heart surgery. In the study researching alcohol septal ablation for obstructive HCM, 15 patients received the procedure. Researchers concluded that obstructive HCM was at least in part reversible with alcohol septal ablation due to its ability to improve oxygen delivery to the heart and improve myocardial energetics, which is the heart’s use of energy in relation to its ability to pump blood.


Further research could potentially lead to better screening for asymptomatic HCM carriers and the development of early treatments that could halt or at least postpone full onset of the disease.


For more information:


Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Clinical Study | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init